AMG National Trust Bank Buys New Stake in IQVIA Holdings Inc. $IQV

AMG National Trust Bank bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,549 shares of the medical research company’s stock, valued at approximately $3,713,000.

Other hedge funds have also modified their holdings of the company. Physician Wealth Advisors Inc. lifted its position in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares in the last quarter. Westside Investment Management Inc. boosted its position in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new position in IQVIA during the third quarter valued at approximately $36,000. Root Financial Partners LLC acquired a new position in IQVIA in the 3rd quarter valued at approximately $43,000. Finally, Hantz Financial Services Inc. lifted its position in IQVIA by 92.0% in the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after buying an additional 115 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup reduced their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 target price on IQVIA in a report on Friday, February 6th. Jefferies Financial Group reduced their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Barclays decreased their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.20.

IQVIA Stock Down 2.2%

NYSE IQV opened at $165.63 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. The stock’s 50 day simple moving average is $217.61 and its 200 day simple moving average is $208.27. The firm has a market cap of $28.11 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the prior year, the firm posted $3.12 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.